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Bladder secretion of inhibitors of calcium oxalate crystal growth.
Differences in calcium oxalate crystal growth inhibition were studied in
normally voided urine (bladder urine) and in urine collected directly
from the kidney (kidney urine) in nine dogs. Urine samples were
collected before and 10 days after bilateral ureterostomies. Calcium
oxalate crystal growth inhibition was measured in a standard seeded
crystal growth system. The alcian blue-precipitable material of the urine
samples was determined. Significantly lower values were observed in
kidney urine than in bladder urine for calcium oxalate crystal inhibition
(mean difference, 0.07 0.02 inhibitor units/mg creatinine; P < 0.01)
and for the alcian blue-precipitable material (mean difference, 0.07
0.02 mg/mg creatinine; P < 0.01). We conclude that the bladder adds
calcium oxalate crystal growth inhibition to urine. Glycosaminoglycans
from the bladder mucosa may be responsible; however, other acidic
polymers such as RNA fragments or glycopeptides have been shown to
be a constituent of the alcian blue-precipitable material. These are
potent inhibitors of calcium oxalate crystal growth, and their participa-
tion in the increase of inhibition observed in bladder urine cannot be
excluded. Total calcium oxalate crystal growth inhibition present in
normally voided urine may be an overestimation of the actual inhibition
present at the level of the kidney, where calculi usually form.
Sécrétion vésicale d'inhibiteurs de Ia croissance des cristaux d'oxalate
de calcium. Les differences dans l'inhibition de Ia croissance des
cristaux d'oxalate de calcium ont été étudiées dans des urines Cmises
normalement (urines vésicales) et dans des urines directement
collectCes dans le rein (urines rCnales) chez neuf chiens. Les Cchantil-
Ions urinaires ont etC collectCs avant et 10 jours après urCtérostomie
bilatCrale. L'inhibition de Ia croissance des cristaux d'oxalate de
calcium a eté mesurCe dans un système de croissance standard autour
d'un cristal. Le materiel prCcipitable au bleu alcian dans les échantillons
urinaires a etC dCterminC. Des valeurs significativement moindres ont
etC observdes dans les urines rénales par rapport aux urines vCsicales
pour l'inhibition des cristaux d'oxalate de calcium (diffdrence moyenne,
0,07 0,02 unites inhibitrices/mg créatinine; P < 0,01) et pour Ic
materiel précipitable au bleu alcian (difference moyenne 0,07 0,02
mg/mg crëatinine; P < 0,01). Nous concluons que Ia vessie ajoute un
inhibiteur de Ia croissance des cristaux d'oxalate aux urines. Les
glycosaminoglycans de Ia muqueuse vCsicale pourraient ètre
responsables; cependant, d'autres polymeres acides, comme des frag-
ments de RNA ou des glycopeptides pourraient Ctre des constittiants du
materiel precipitable au bleu alcian. Ce sont des inhibiteurs puissants de
Ia croissance des cristaux d'oxalate, et leur participation a l'augmenta-
tion de l'inhibition observée dans les urines vCsicale ne peut être
exclue. L'inhibition totale de La croissance des cristaux d'oxalate de
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calcium prCsente dans les urines normalement émises pourrait Ctre une
surestimation de Ia veritable inhibition prCsente au niveau renal, oU les
calculs se forment d'habitude.
The presence of inhibitors of calcium oxalate crystal growth
and aggregation in urine has been considered important for the
prevention of calcium oxalate stone formation because urine
usually is supersaturated with calcium oxalate [1]. A decrease
of inhibitory activity in the urine of patients who form calcium
oxalate calculi within the urinary tract has been suggested as a
risk factor for calcium stone formation [21. Yet, measurements
of the total inhibitory activity in 24-hr urine specimens from
normal subjects and from patients with idiopathic formation of
calcium oxalate stones have led to conflicting results.
Robertson et al [2] reported a decrease in the urinary excretion
of calcium oxalate crystal growth inhibitors in patients with
idiopathic calcium urolithiasis. Their data showed a wide over-
lap between the individual values of inhibitory activity for
patients in whom stones formed and for normal subjects.
Conversely, others [3, 4] found no differences in the level of
calcium oxalate crystal growth inhibition in 24-hr urine speci-
mens from patients with calcium oxalate stones and from
normal subjects.
The fact that the uroepithelium of the bladder is covered with
the glycocalyx-containing glycosaminoglycans [5, 61 and that
glycosaminoglycans have been shown to be potent inhibitors of
both calcium oxalate crystal growth and aggregation [7, 81
suggests that the bladder may not behave as an inert reservoir
in terms of calcium oxalate crystal formation. In a preliminary
report, Edyvane, Ryall, and Marshall [9] noted a significant
amount of inhibitory activity in saline washes of the bladder.
This observation suggested that some of the inhibition of
calcium oxalate crystal formation observed in voided urine
specimens may come from the bladder. The possibility that
urine contains significant amounts of calcium oxalate crystal
growth inhibitors that are of bladder origin might have two
major consequences. First, measurements of calcium oxalate
crystal growth inhibition in voided urine would overestimate
the inhibition present at the level of the kidney, where calcium
oxalate stones usually form. Second, this possibility could
explain the apparent lack of difference in the amount of calcium
oxalate crystal growth inhibition between normal subjects and
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patients with idiopathic calcium oxalate urolithiasis, as reported
in some studies [3, 4].
The purpose of this study was to compare the amount and
chemical nature of the inhibition of calcium oxalate crystal growth
present in kidney urine with that present in voided (bladder) urine.
Methods
Nine female mongrel dogs weighing 13.8 2.0 kg were used
in these experiments. They were fed the same standard diet 4
days before the experiment and for its duration.
Technique of tubeless ureterostomies. Operation was per-
formed with the dogs under phenobarbital anesthesia. The
ureters were approached through a midline incision and were
dissected away from the retroperitoneal space, and care was
taken to preserve most of the vascular supply. After each ureter
had been mobilized from the bladder junction to the lower pole
of the kidney, it was divided at the ureterovesical junction. A
tunnel was formed in the abdominal muscle and skin 5 cm below
the costal margin on each side. The muscular tunnel easily
accommodated the size of a finger. The skin orifice was 1.5 by
0.5 cm and rectangular. The ureter was then pulled through this
musculocutaneous tunnel, and any twisting or tension was
avoided. The distal 1 cm of the ureter was split longitudinally
into two parts [10]. Each ureter was then anchored to the
underlying tissues and sutured to the skin with 6/0 nylon sutures
in order to fill the rectangular skin defect that was formed
previously.
The dogs were given a 3-day course of antibiotics (penicillin-
Colistimethate, 1 million units/day) and were kept in metabolic
cages to provide good drainage of urine and to prevent skin
irritation. Excretory urograms were performed with the intra-
venous injection of 30 ml of contrast medium (Hypaque-M,
90%) 18 days after operation. If ureteral dilatation was present,
the dog was excluded from the study. Blood samples were
withdrawn pre-operatively and 3 weeks post-operatively (at
sacrifice) for the determination of serum creatinine.
Technique of urine collection.The periods of urine collection
started 1 hr after the morning meal and lasted 6 hr. The dogs had
free access to water during all collection periods. Two collec-
tions of bladder urine and kidney urine were available in each
dog. The urine was kept frozen until processed for the mea-
surement of calcium oxalate crystal growth inhibition, alcian
blue-precipitable material, calcium, and creatinine.
Bladder (pre-operative) collections were performed in two
ways. The first collection was made in a metabolic cage. When
a dog did not micturate during the period of observation (6 hrs),
the collection period was extended until urine was found in the
collecting device. Although this method did not allow accurate
6-hr collections of urine, it was preferable to bladder
catheterization, which would have required anesthesia and
could have produced irritation of the bladder mucosa. A second
collection was performed at the time of operation by direct
suprapubic puncture and evacuation of the bladder. Operation
was scheduled during the afternoon so that urine collected at
that time corresponded to a 6-hr postprandial collection.
Kidney urine was collected 10 days after operation on 2
consecutive days. A collecting device, including a belt that
supported two receptacles, was tightened on the dog's abdo-
men. The orifices of the two receptacles were applied to the
ureterostomies. Because of the fragility of this device in asso-
ciation with the dog's movements, semi-immobilization in a
harness was necessary. This collection device was satisfactory
because it did not allow leakage of the urine. After collection,
urine from the two kidneys was pooled before freezing.
Measurements of calcium oxalate crystal growth inhibitors.
A seeded crystal growth system [11] was used to measure the
inhibition present in the urine samples. In this system, one
inhibitor unit corresponds to that concentration of any inhibitor
of crystal growth necessary to produce a 50% reduction in the
rate of crystal growth [12]. Results were expressed as inhibitor
units per liter.
Determination of the concentration of alcian blue-precipita-
ble material. The concentrations of alcian blue-precipitable
material in the urine samples were determined by the method of
Whiteman [13]. Fifty microliters of urine was mixed with 1 ml of
reagent that contained 0.05% alcian blue 8GN (MCB Chemi-
cals, subsidiary of EM Science, Cincinnati, Ohio, USA), 50mM
magnesium chloride, and 50 m sodium acetate buffer adjusted
to pH 5.8 with acetic acid. After 2 hrs, the aliquots were
centrifuged and the precipitate was washed with 2 ml ethanol
and dissociated with 1 ml of 40% Manoxol lB (BDH Chemicals,
England). The absorbence of the resulting blue solution was
measured on a spectrophotometer (DMS 90, Varian Associates,
Inc., Sunnyvale, California, USA) at 620 nm. The content of
alcian blue-precipitable material in the samples was determined
by a reference curve, and chondroitin 4 sulfate (Grade III,
Sigma Chemical Co., St. Louis, Missouri, USA), was used as a
standard. All samples were analyzed in duplicate, and concen-
trations were expressed in milligrams per liter.
Analysis of data
The amounts of calcium oxalate crystal growth inhibition and
alcian blue-precipitable material were expressed as inhibitor
units per liter and milligrams per liter, respectively, divided by
the creatinine concentration in milligrams per liter of the
sample. The two values obtained for kidney and bladder urine
were averaged. Analysis of the difference between kidney and
bladder urine was done by the sign test.
Results
Normal renal function and absence of dilatation of the
urinary tract. Plasma creatinine values were 1.05 0.15 mg/dl
pre-operatively and 0.97 0.16 mg/dl post-operatively. The
hourly creatinine excretion was 28 4 mg, a value that is not
different from the value of 26 5 mg observed in normal dogs.
Excretory urograms showed normal upper urinary tracts and
ureters without obstruction.
Calcium oxalate crystal growth inhibition. The amount of
calcium oxalate crystal growth inhibition per milligram of
creatinine showed an increase in each animal from kidney urine
(0.07 0.01 inhibitor units/mg creatinine) to bladder urine (0.14
0.03 inhibitor units/mg creatinine). Changes between kidney
and bladder urine were statistically significant (mean change,
0.07 0.02; P < 0.01). The increase in calcium oxalate crystal
growth inhibition observed in bladder urine was 104 30% of
the value found in kidney urine (Fig. 1, left).
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Mean change = 0.07 0.02 Mean change = 0.07 0.02
Mean increase: 104 30% Mean increase: 73 22%
P<0.01 P<0.ol
Fig. 1. Left Calcium oxalate (Ca Ox) crystal growth inhibition in kidney
and bladder urine. Right Alcian blue-precipitable material (ABPM) in
kidney and bladder urine. Abbreviations are: creat, creatinine; IU,
inhibitor units.
Kidney Bladder 20,000 and 150,000, the molar concentration that would give I
inhibitor unit would be between 10-8 and i0—. In comparison,
4.6 x 10 M chondroitin sulfate from shark cartilage, 6.3 x
1O M hepann, and 3.2 x iO M RNA from yeast will produce
1 inhibitor unit [IS]. This would suggest that something other
than chondroitin sulfate is responsible for the added inhibition
in bladder urine observed in our study. However, it is unlikely
that urinary chondroitin sulfate is identical to that obtained
from shark cartilage. Glycosaminoglycans isolated from urine
have been shown to be more potent inhibitors of calcium
oxalate crystal growth than those obtained commercially [16].
Participation of other polyanions, such as the acidic urinary
glycoprotein described by Ito and Coe [17], also a potent
inhibitor of calcium oxalate crystal growth, cannot be excluded.
The presence of glycosaminoglycans on the bladder mucosa [6]
makes them an available source of the increased inhibition
observed in bladder urine, but other more potent inhibitors may
be involved.
The fact that urine contains less calcium oxalate inhibition in
the kidney than in the bladder increases the relative importance
of the inhibitors that are known to be present in kidney urine in
patients with calcium oxalate stone formation. Low molecular
weight inhibitors such as citrate [12] and pyrophosphate [18] are
excreted at the level of the renal tubule and, therefore, are
present in kidney urine. These two substances contribute 10 to
15% of the total calcium oxalate inhibition observed in voided
(bladder) urine [8]. Because kidney urine contains about 50%
less inhibition than voided urine, pyrophosphate and citrate
could contribute 20 to 30% of the total inhibition present in
kidney urine. Therefore, citrate and pyrophosphate would seem
to be more important in calcium oxalate inhibition and stone
formation than thought previously, and medical treatment that
increases the urinary excretion of citrate and pyrophosphate
should benefit patients with calcium oxalate stones. Some high
molecular weight inhibitors, such as glycopeptide isolated from
human kidney tissue culture, may also be present at the level of
the kidney [19]. The contribution of this glycopeptide to cal-
cium oxalate crystal growth inhibition, estimated to be 18 to
50% in voided urine [17], would be increased in urine at the
level of the kidney.
The increase in calcium oxalate crystal growth inhibition in
Concentration of alcian blue-precipitable material. The
amount of alcian blue-precipitable material similarly showed an
increase from kidney urine (0.087 0.009 mg/mg creatinine) to
bladder urine (0.16 0.03 mg/mg creatinine). The mean change
(0.07 0.02 mg/mg creatinine) was statistically significant (P <
0.01). The increase in the content of alcian blue-precipitable
material observed in bladder urine was 73 22% of the value
found in kidney urine (Fig. 1, right).
Discussion
An increase in calcium oxalate crystal growth inhibition as
urine moved from the kidney to the bladder and a parallel
increase in the alcian blue-precipitable material were observed
in this study. The contribution of the bladder is substantial; the
mean increases in inhibition of calcium oxalate crystal growth
and in alcian blue-precipitable material in bladder urine were
104 30% and 73 22%, respectively.
In urine, substances that precipitate with alcian blue include
glycosaminoglycans, Tamm-Horsfall protein, RNA fragments
[8], and possibly other acidic polyanions. After removal of
Tamm-Horsfall protein, which is not a calcium oxalate crystal
growth inhibitor in our seeded crystal growth system (unpub-
lished results), glycosaminoglycans account for the main part of
the alcian blue-precipitable material in urine by weight [13].
Other polyanions, such as RNA that precipitates with alcian
blue, are believed to be present in urine in small quantities
(from 5 to 20 mg/liter) and would account for approximately 2%
of the alcian blue-precipitable material [8, 14]. The alcian
blue-precipitable substance added to urine by the bladder was
not characterized in our study.
If we assume that the increase in alcian blue-precipitable
material found in bladder urine (mean change, 0.07 0.02
mg/mg creatinine) was responsible for the increase in inhibition
(mean change, 0.07 0.02 inhibitor units/mg creatinine), it is
possible to estimate the concentration at which the alcian
blue-precipitable substance would give I inhibitor unit. If we
assume that the molecular weight of this substance is between
bladder urine compared with kidney urine observed in this
study leads to three observations and speculations that may be
of clinical importance: 1) the measurement of calcium oxalate
crystal growth inhibition in voided urine may be an inaccurate
estimation of the inhibition present at the level of the kidney; 2)
citrate and pyrophosphate, as well as other inhibitor substances
of renal origin, may be more important inhibitors than thought
previously; and 3) the study of the characterization and sepa-
ration of the inhibitors of calcium oxalate crystal formation may
be more fruitful when it is performed with kidney urine.
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